OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease	479
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	217
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis	200
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	131
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease	123
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	119
Neuropathology and molecular diagnosis of Synucleinopathies	118
Tauopathies: new perspectives and challenges	115
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	113
Solving neurodegeneration: common mechanisms and strategies for new treatments	110
TDP-43 Pathology in Alzheimer’s Disease	110
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	109
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	106
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	105
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	104
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	103
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	102
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease	102
Cellular and pathological heterogeneity of primary tauopathies	101
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	100
New approaches to symptomatic treatments for Alzheimer’s disease	96
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	95
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	94
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	90
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	84

Glycosphingolipids and neuroinflammation in Parkinson’s disease	80
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	80
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	79
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	79
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	76
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice	73
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers	70
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	68
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	66
Microbial involvement in Alzheimer disease development and progression	62
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	59
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	59
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	59
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations	57
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	57
The role of inflammasomes in vascular cognitive impairment	54
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	51
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	51
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions	50
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	50
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	48
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	47
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma	47
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	47
The informed road map to prevention of Alzheimer Disease: A call to arms	46
Alzheimer’s disease – the journey of a healthy brain into organ failure	45
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1	45
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease	45
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	44
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	44
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice	43
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	43
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	43
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains	42
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments	41
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	41
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain	41
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	41
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	39
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	38
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	38
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease	38
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease	37
Sleep and circadian rhythms in Parkinson’s disease and preclinical models	36
Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease	35
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	35
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration	35
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models	35
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	35
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	34

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	34
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	34
Basal lamina changes in neurodegenerative disorders	33
LRP1 is a neuronal receptor for α-synuclein uptake and spread	33
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	32
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	32
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	32
BIN1 protein isoforms are differentially expressed in astrocytes, neurons, and microglia: neuronal and astrocyte BIN1 are implicated in tau pathology	31
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	31
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo	31
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model	31
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	30
Tau interactome and RNA binding proteins in neurodegenerative diseases	30
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	30